<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693026</url>
  </required_header>
  <id_info>
    <org_study_id>M.A.R.M.C.D./2020/2637</org_study_id>
    <nct_id>NCT04693026</nct_id>
  </id_info>
  <brief_title>Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients</brief_title>
  <official_title>Efficacy of Ramdicivir and Baricitinib Combination Therapy for the Treatment of COVID 19 ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M Abdur Rahim Medical College and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First affiliated Hospital Xi'an Jiaoting University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M Abdur Rahim Medical College and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination&#xD;
      therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by&#xD;
      Coronavirus disease 2019 (COVID-19). Our aim is to compare the outcome of the &quot;Remdesivir +&#xD;
      Baricitinib&quot; combination against &quot;Remdesivir + Tocilizumab&quot; therapy and find the best option&#xD;
      for the management of ARDS in COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">March 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Clinical Improvement (TTCI)</measure>
    <time_frame>Following randomization 30 days</time_frame>
    <description>Time to Clinical Improvement (TTCI) Defined as Time from Randomization to National Early Warning Score 2 (NEWS2) Score of &lt;/= 2 Maintained for 24 Hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>Following randomization 30 days.</time_frame>
    <description>Mortality Rate on Days during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>Following randomization 30 days.</time_frame>
    <description>Duration of ICU Stay in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration total hospital stay</measure>
    <time_frame>Following randomization 30 days.</time_frame>
    <description>Duration of hospital stay in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of daily Supplemental Oxygen Use</measure>
    <time_frame>Following randomization 30 days.</time_frame>
    <description>Rate of daily Supplemental Oxygen Use by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Failure</measure>
    <time_frame>Following randomization 30 days.</time_frame>
    <description>Time to Clinical Failure, Defined as the Time from Randomization to the First Occurrence of Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <condition>Covid-19 ARDS</condition>
  <arm_group>
    <arm_group_label>Group A: Remdesivir + Baricitinib treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remdesivir (Injectable solution):&#xD;
A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (&gt;40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (&gt;40kg) daily following randomization.&#xD;
+&#xD;
Baricitinib (oral tablet form):&#xD;
Baricitinib tablets 4 mg/day for 2 to 4weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Remdesivir + Tocilizumab treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remdesivir (Injectable solution) A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (&gt;40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (&gt;40kg) daily following randomization.&#xD;
+&#xD;
Tocilizumab (Injectable solution):&#xD;
Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Remdesivir 100 IV Infusion as a lyophilized powder</description>
    <arm_group_label>Group A: Remdesivir + Baricitinib treatment group</arm_group_label>
    <arm_group_label>Group B: Remdesivir + Tocilizumab treatment group</arm_group_label>
    <other_name>Ninavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Baricitinib oral tablet form</description>
    <arm_group_label>Group A: Remdesivir + Baricitinib treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab IV Infusion</description>
    <arm_group_label>Group B: Remdesivir + Tocilizumab treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Severe COVID-19 patients require hospitalization under HDU/ICU. The SARSCoV-2 infection&#xD;
        will be confirmed by RT PCR / CT Chest in every case.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants with uncontrolled clinical status who were hospitalized from the before.&#xD;
        Contraindication / possible drug interaction. Participants who have any severe and/or&#xD;
        uncontrolled medical conditions like, Severe ischemic heart disease, epilepsy, malignancy,&#xD;
        Pulmonary/ renal/hepatic disease, AIDS, Pulmonary TB, pregnancy, Corpulmonale, and etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akter Kamal, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>M Abdur Rahim Medical College and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD</last_name>
    <phone>008801817711079</phone>
    <email>dr_mohiuddinchy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Akter Kamal, MD, PhD</last_name>
    <phone>008801817233991</phone>
    <email>kamalaktar@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>M. Abdur Rahim Medical College Hospital</name>
      <address>
        <city>Dinajpur</city>
        <zip>5200</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akter Kamal, MD, PhD</last_name>
      <phone>0088017233991</phone>
      <email>kamalaktar@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD</last_name>
      <phone>008801817711079</phone>
      <email>dr_mohiuddinchy@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital Xi'an Jiaotong University</investigator_affiliation>
    <investigator_full_name>Abu Taiub Mohammed Mohiuddin Chowdhury</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <keyword>Covid-19 ARDS</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Remdicivir</keyword>
  <keyword>Baricitinib</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

